CAR-T cell therapy in cancer: Clinical applications, challenges in solid tumors, and emerging strategies
Cambridge Journal of Student Research · 2026 · 1 (1)
DOI: 10.69058/g5s0rfwemk75 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cambridge Journal of Student Research, 2026. Verfasst von Wenhan Jiang.
Abstract (Originalsprache)
Cancer treatment increasingly incorporates precision and immune-based therapies alongside surgery, chemotherapy, and radiotherapy, shifting from conventional approaches that directly damage or remove tumors toward precision strategies that involve genetically engineering autologous or donor-derived T cells to recognize selected surface antigens on cancer cells. Chimeric antigen receptor T-cell therapy represents one of the most clinically developed examples of this shift by re-engineering T cells to target specific cancer-associated antigens. While CAR-T therapies have achieved durable responses in hematologic malignancies, translating these clinical successes to solid tumors presents a formidable biological barrier. A major challenge is identifying antigens that are consistently expressed by tumor cells but absent or minimally expressed in healthy tissues. Success also hinges on navigating an intricate and hostile tumor microenvironment characterized by antigen heterogeneity, dense extracellular matrices that restrict immune infiltration, pervasive immunosuppressive signaling cascades, and chronic antigen exposure that induces premature T-cell exhaustion. Consequently, optimizing therapeutic efficacy requires a dual approach that addresses both T-cell intrinsic biology and host tissue landscapes. This review examines the applications of CAR-T therapy in hematologic cancers, the barriers limiting its effectiveness in solid tumors, and the emerging strategies that aim to address these limitations. These include multi-antigen logic gating to prevent antigen escape, cytokine-armored vectors to remodel local immunosuppression, and in vivo approaches to simplify manufacturing. Ultimately, overcoming current clinical bottlenecks will require engineering context-aware CAR-T platforms tailored to the complex biological realities of individual solid tumors.
Zitieren
APA
Jiang, W. (2026). CAR-T cell therapy in cancer: Clinical applications, challenges in solid tumors, and emerging strategies. Cambridge Journal of Student Research, 1(1). https://doi.org/10.69058/g5s0rfwemk75
Vancouver
Jiang W. CAR-T cell therapy in cancer: Clinical applications, challenges in solid tumors, and emerging strategies. Cambridge Journal of Student Research. 2026;1(1). doi:10.69058/g5s0rfwemk75
BibTeX
@article{Jiang2026,
author = {Jiang, Wenhan},
title = {CAR-T cell therapy in cancer: Clinical applications, challenges in solid tumors, and emerging strategies},
journal = {Cambridge Journal of Student Research},
year = {2026},
volume = {1},
number = {1},
doi = {10.69058/g5s0rfwemk75}
}
EUVIMED